What is novel is that Catalyst failed twice, not once......on the same compound for the same indication. Doh! to boot, these boneheads couldn't even hit a single primary or secondary endpoint of the very trial which they designed. Keep issuing shares and raising money!
How well did vigabatrin attenuate opioids in the 2 clinical trails that Catalyst conducted.....oh yeah, it didn't hit a single primary or secondary endpoint. Maybe you should review Catalysts clinical blow-ups before investing in the "next big thing".
When Piper is the lead underwriter on the next share issuance from Catalyst, the price will go up to $9/share.
A VP of Corporate Development who's only corporate development has been his own promotion after 5 months on the job. What happened to all those Catalyst "assets" that you were going to "leverage" into a "partnering opportunity"? Holding out for the big pharma bucks, huh?
Are you familiar with any microcap biotechs that are on the verge of a NDA with a "pipeline in a pill" sitting in the background that DONT have a major pharma development partnership in place? Exactly.....I'm sure several firms have done due diligence and Catalyst didn't pass the sniff test. That's what happens when you have a CEO who has been sanctioned TWICE for embellishing product prospects to investors.
Hey idiot.....take a look at the "high quality" institutional investors who "bought in for the long term" last time. New Leaf? Gone. Orbimed? Gone. Perceptive? Gone. This dog is headed down sooner or later as there is no way on earth these con men will ever launch a drug.
Keep dreaming sunshine. Ever get the feeling that you've been had? Big things, just around the corner......just don't ask which corner.
If you are a new investor, don't expect much except moving deadlines, positive forward looking statements and ultimately trial failure. These Florida con men ran trials on the same compound TWICE and both times they were unable to hit ANY primary endpoints in Phase III. All the while, these same guys were raising money hand over fist while talking up the company's prospects. The CEO has been sanctioned twice for making misleading statements concerning his firm's products.....nuff said.
Just more fundraising and promises of future greatness......Ka-ching! These losers paid a 10% placement fee and they couldn't even pick up coverage from the underwriting brokers. Hilarious! A biotech shell company if ever there was one!
Once again reinforcing that Catalyst's well paid leadership has more money than brains. Pat has bought how many shares of this train wreck in the open market? The guy owns millions of direct shares and shareholders are still down 50% from where this dog IPO'd.
Both of them seem to have an undying affection for Catalyst leadership no matter how much abuse Pat & the gang inflict on them. Like an abused captive, both idiots always have a rationalization, excuse, explanation for why Catalyst exaggerates drug efficacy claims, clinical data timelines, issues dilutive shares, can't attract nor retain pedigreed employees, etc. Sad, so sad.....since Catalyst cant seem to generate clinical data on Tourettes, maybe they can use CPP109 for a Stockholm Syndrome indication and get these two clowns the help they need.
Nope, still bashing away on this easy target....when do you think these senior citizens will raise money thru dilutive share issuance? Tick tock, tick tock.....you know its coming. Get your rationalizations ready for the inevitable sucker. Since your so gullible, perhaps I can sell you some Florida swampland....much like Catalyst, its the next big thing.....get in now fool!
Management is a total joke.........they "expect" to hold a meeting in Q1 with the FDA......is this similar to how they "expected" to release CPP109 top line data in Q4 of 2014? Wouldnt you know an exact date for your expected Q1 meeting by late January or does the FDA just pick up the phone and tell Pat to come on down? The EAP has been enrolling for 3 months.....how many patients are now being dosed? The Chief Commercial Officer has been in place for 4 months now.....what partnership or other business development activity has been closed during this time? The BOD now has only 4 members, 2 of which have exceptionally close business ties outside of Catalyst.....when will a new BOD member be appointed if ever?
Keep the illusion going and keep the music playing......I bet the next issuance will be @ 2.25 or lower. Welcome new suckers!
Guess its pretty easy to tell which company Wall Street prefers. 4 months into the job, not a single new item on the corporate development side of the house, just an "update" which is a restatement of the old update. Typical biotech penny stock stuff....where is the new head of patient advocacy? Did he size up the situation and disappear like Barrett McGrath?
Yep.....add those 50k to his 3.9 million....look at the stock race forward.....looks like you are back to even champ!
These guys are a joke.